CG Oncology, Inc. Common stock (CGON) Stock

CG Oncology, Inc. Common stock (CGON) is a Healthcare stock trading at $61.08 (as of 2026-06-18), with a market capitalization of $5.49B and a trailing P/E of -25.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

CG Oncology, Inc. is a clinical biopharmaceutical company developing and commercializing a bladder-sparing therapeutic for people with bladder cancer. Its lead candidate, cretostimogene, is in clinical development for patients with high-risk non-muscle invasive bladder cancer who do not respond to BCG therapy.

Valuation — source: SEC EDGAR (first-party)
Price$61.08
Market Cap$5.49B
P/E Ratio-25.5
EV / EBITDA-24.6
Price / Book4.81
Price / Sales1035.96
DCF Value (model)$-26.36
DCF Upside vs Price-143.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$4.04M
Net Margin-3985.0%
Return on Equity-17.1%
Debt / Equity0.00
Current Ratio31.30
Revenue Growth (YoY)254.7%
EPS Growth (YoY)47.5%
FCF Growth (YoY)67.8%
Financial Health — source: SEC EDGAR
Altman Z-Score79.00 (safe)
Valuation vs Sector & Industry
Stock P/E-25.5
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-221.4%
vs Industry-247.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRTW INVESTMENTS, LP ($472.73M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOArthur Kuan
Employees113
CountryUS
IPO Date2024-01-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Ligand Pharmaceuticals Incorporated (LGND)
  • Corcept Therapeutics Incorporated (CORT)
  • Arcutis Biotherapeutics, Inc. (ARQT)
  • Kiniksa Pharmaceuticals, Ltd. (KNSA)
  • Dyne Therapeutics, Inc. (DYN)
  • IDEAYA Biosciences, Inc. (IDYA)
  • Nuvation Bio Inc. (NUVB)
  • Disc Medicine, Inc. (IRON)
CGON earnings history · CGON institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.